Abstract
A public heath problem, osteoporosis, is recognized as the prevalent disease, and mainly causes for impairment and loss mass of bone. It closely related the balance between bone formation by osteoblasts and resorption by osteoclasts during the remodeling cycle of bone. Hence, pharmaceutical therapies are looking for the potential agents to stimulate osteoblastic bone formation, as well as inhibit osteoclastic processes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.